logo
AI is 'bailing out' most of the U.S. stock market, Josh Brown says

AI is 'bailing out' most of the U.S. stock market, Josh Brown says

CNBC4 days ago
Concentrated tech strength is powering a market that is otherwise flashing signs of falling consumer health, according to Josh Brown, CEO of Ritholtz Wealth Management. Concerns around the market are mounting as artificial intelligence-related capex spending and strong corporate earnings — notably from Meta and Microsoft reports this week — fuel record gains for just a few mega-cap tech companies, while the rest of the S & P 500 is posting lackluster returns. "The top five market cap stocks now, all AI, spoiler alert, I think they're equal to the market cap of the bottom 430 S & P 500 names. That's absurd — and the problem is it was absurd when they were equal to the bottom half of the S & P 500," Brown said Thursday on CNBC's " Halftime Report ." By market cap, Nvidia is the largest company in the broad-market index worth about $4.37 trillion. Microsoft earlier Thursday joined the exclusive $4 trillion club on the back of its better-than-expected earnings report, but later climbed down to roughly $3.97 trillion. Apple, Amazon and Google parent Alphabet are the following largest names in the S & P 500, according to their respective market cap sizes. As these stocks continue to get a pop, Brown called out a dangerous shift in investor focus toward AI and away from stocks considered as "bellwether" indicators of U.S. economic and consumer health. "Nobody seems to care. Chipotle is a falling knife. Nike's been horrible. Starbucks, horrible. And these are companies where when they used to report, we would be like, ooh, the health of the consumer. Forget it. No cares," Brown said. "They keep going lower, and AI keeps bailing out the rest of the stock market." "Some of the other companies that we used to see as bellwethers are doing very poorly ... we're not paying attention to that because we're so focused on this," he said, referring to AI. He recalled the dotcom bubble in the late 1990s when traders overlooked bright spots in the market that were not related to the Internet. "It's not that there aren't opportunities. It's a game where you say to yourself, but other investors aren't going to come and buy this stock for me higher 'cause they only want to buy one thing. It's not healthy. We get to that point," Brown said. DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. INVESTING INVOLVES RISK. EXAMPLES OF ANALYSIS CONTAINED IN THIS ARTICLE ARE ONLY EXAMPLES. THE VIEWS AND OPINIONS EXPRESSED ARE THOSE OF THE CONTRIBUTORS AND DO NOT NECESSARILY REFLECT THE OFFICIAL POLICY OR POSITION OF RITHOLTZ WEALTH MANAGEMENT, LLC. JOSH BROWN IS THE CEO OF RITHOLTZ WEALTH MANAGEMENT AND MAY MAINTAIN A SECURITY POSITION IN THE SECURITIES DISCUSSED. ASSUMPTIONS MADE WITHIN THE ANALYSIS ARE NOT REFLECTIVE OF THE POSITION OF RITHOLTZ WEALTH MANAGEMENT, LLC" TO THE END OF OR OUR DISCLOSURE. Click here for the full disclaimer.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Atombeat and BioDuro link for peptide drug discovery platform
Atombeat and BioDuro link for peptide drug discovery platform

Yahoo

time8 minutes ago

  • Yahoo

Atombeat and BioDuro link for peptide drug discovery platform

Atombeat and BioDuro have announced a strategic partnership to launch an AI-powered platform aimed at accelerating peptide drug discovery. The collaboration combines Atombeat's expertise in in silico modelling with BioDuro's capabilities in discovery chemistry, biology, and drug metabolism and pharmacokinetics. The initiative is set to enhance the development of next-generation peptides, quality candidates with quick timelines and cost-effectiveness across various therapeutic areas. Atombeat expedites the discovery of drugs using its Hermite software and RiDYMO platform, incorporating technologies such as Uni-Dock and Reinforced Dynamics. These tools enable the exploration of a digital library with over one trillion potential peptide compounds, streamlining the early drug discovery process. By focusing on the most promising candidates, the platform is designed to save cost, time and effort in drug development. BioDuro's role in the partnership is to leverage its synthesis capability for producing several peptide compounds in parallel. The company will be able to deliver pure peptides within one week, without the need for purification steps. This integrated approach aims to significantly reduce research and development timelines and associated costs and risks. BioDuro CEO Dr Armin Spura stated: 'We are excited to advance peptide innovation through our strategic partnership with Atombeat. Atombeat brings extensive experience in AI-assisted drug design and optimisation. 'Together, we aim to provide the industry with leading services in peptide drug development, accelerating smarter and more efficient peptide research, and delivering faster and comprehensive solutions to our global clients.' The AI-accelerated platform will facilitate a seamless workflow from molecular design to preclinical candidate selection. It is expected to deliver cyclic peptides that meet key developability traits, such as membrane permeability, across a broad range of therapeutic areas. "Atombeat and BioDuro link for peptide drug discovery platform" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Amphenol to buy CommScope's broadband connectivity, cable unit for $10.5 billion
Amphenol to buy CommScope's broadband connectivity, cable unit for $10.5 billion

Yahoo

time8 minutes ago

  • Yahoo

Amphenol to buy CommScope's broadband connectivity, cable unit for $10.5 billion

(Reuters) -Fiber-optic cable maker Amphenol said on Monday it will buy CommScope's connectivity and cable solutions business for $10.5 billion in an all-cash deal. Shares of CommScope surged 42% in premarket trading, while Amphenol rose about 2%. The transaction aims to bolster Amphenol's portfolio, particularly by adding fiber optic interconnect products for artificial intelligence and other data center applications. The deal is expected to close in the first half of 2026 and will add to Amphenol's diluted earnings per share in first full year after closing. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Big Tech's AI Spend Could Reach $400 Billion
Big Tech's AI Spend Could Reach $400 Billion

Yahoo

time8 minutes ago

  • Yahoo

Big Tech's AI Spend Could Reach $400 Billion

Microsoft (NASDAQ:MSFT) and Meta (NASDAQ:META) are pushing Big Tech's AI infrastructure spend toward an estimated $400 billion, with public filings already showing $344 billion this year. The increase is funding data centers, AI ready servers and model training as Morgan Stanley sees the surge adding up to 0.5% to U.S. GDP in 2025 and 2026 and projects $2.9 trillion in related investment from 2025 to 2028. Warning! GuruFocus has detected 7 Warning Sign with MSFT. Microsoft set a record with $24.2 billion in capex last quarter and plans more than $30 billion this quarter, while Amazon (NASDAQ:AMZN) logged $31.4 billion, and Alphabet raised its full year capex forecast to $85 billion. Meta raised the low end of 2025 guidance and is expanding its internal AI unit, signaling further planned Street has reacted unevenly: Microsoft and Meta shares climbed, with Microsoft hitting a $4 trillion value and Meta up more than 8%, while Amazon slid 8% after weak cloud results. Apple remains an outlier with $9.47 billion invested over nine months, up 45% year over year, prioritizing efficiency. This article first appeared on GuruFocus. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store